Recent Advances Enabling Enhanced Management of Neurological Disorders

USD 250.00

* Required Fields

USD 250.00

PAY BY INVOICE

Be the first to review this product

Neurological disorders constitute a significant portion of current patient problems, which require better targeted therapeutics. At present there are a plethora of different technologies that will enable early detection of a range of neurological disorders. In this issue of Genetic Technology TOE, a comprehensive overview of point of care diagnostics as well as related biomarkers that will escalate the capability of developing novel therapeutics is presented.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisiti

Table of Contents

Recent Advances Enabling Enhanced Management of Neurological DisordersTechnology ProfilesBlood-Based Biomarkers for Traumatic Brain InjuryUncovering the Genetics of Cognitive FunctionTool for Quantitative Evaluation of Multiple SclerosisNovel Target for Alzheimer’s DiseaseAppendixClinical Trial AnalysisIndustry Interactions




Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.